TMTofy Mussivand

Tofy Mussivand

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tofy Mussivand has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 16 August 2003
      • Vol. 49  (4) , 459-62

    In vivo evaluation of the biocompatibility of the totally implantable ventricular assist device (HeartSaver VAD).

    by Tofy Mussivand, Hiroaki Harasaki, Kenneth Litwak, Mark S Slaughter, Laman A Gray, T Robert D Dowling, Ruedi Mueller, Roy G Masters, Paul J Hendry, Luís Beck-Da-Silva, et al.

    A series of multicenter in vivo studies have been conducted to assess the biocompatibility and device performance of the HeartSaver VAD, a totally implantable pulsatile ventricular assist device (VAD). The experiments (n = 23) were conducted in calves with a mean weight of 101 (75-152) kg. Implants took place at four centers using two different surgical procedures of implantation (one with cardiopulmonary bypass and one without). Three anticoagulation regimens were used (one with continuous intravenous heparin, one with oral warfarin, and one with oral warfarin combined with antiplatelet clopidogrel therapy). Device function and biochemistry were monitored during the study, and organs and device analysis were conducted at explant. There were six nonsurvivors because of early surgical complications (during the first week of support). The postoperative courses in the remaining 17 (74%) calves were uneventful. Hemodynamic and biocompatibility indicators were monitored throughout the study. The mean duration of device support for those cases was 48 (13-92) days. Mean device flow was 7.15 (+/- 1.68) L/min. There were no deaths caused by infection; however, two animals developed endocarditis believed to be caused by the percutaneous instrumentation lines used for the study. No severe bleeding requiring reoperation occurred during the study. The mean plasma free hemoglobin was within normal limits at 6.8 +/- 2.6 mg/dl. Renal and hepatic functions were normal with a mean creatinine of 0.6 +/- 0.1 mg/dl and a mean aspartate aminotransferase of 68.7 +/- 42.6 mg/dl. Several device related improvements were identified and have now been implemented. Additional bovine implants with an optimized device are currently underway in preparation for human trials.


    • 31 March 2003
      • Vol. 19  (4) , 409-12

    Mechanical circulatory support for adolescent patients: the Ottawa Heart Institute experience.

    by Paul J Hendry, Roy G Masters, Ross A Davies, Thierry Mesana, Christine Struthers, Tofy Mussivand, Wilbert J Keon

    Mechanical circulatory support devices may be used for patients with end-stage heart failure for bridging either to cardiac transplant or to recovery of the native heart. While less common in adolescents, fulminant heart failure may be rapidly fatal in these patients unless circulatory support can be instituted. To assess the outcomes and the utility of mechanical circulatory assist devices for children. A retrospective review of pediatric patients (18 years of age or younger) who underwent circulatory support at the Ottawa Heart Institute, Ottawa, Ontario, from 1992 to 2001 was performed using chart audits. Seven patients (four boys, three girls) with a mean age of 14.9 +/- 0.9 years were supported with Thoratec ventricular assist devices (n=6) or a CardioWest total artificial heart (n=1). Preoperatively, the cardiac index was 1.64 +/- 0.2 L/min/m2 on one or two inotropes with ejection fractions of 11 +/- 2.2%. Mean duration of circulatory support was 59.3 +/- 17.2 days with a hospital length of stay of 89.6 +/- 12.8 days. All seven patients underwent successful transplantation and were discharged home. Pediatric patients with fulminant heart failure may be bridged to cardiac transplant successfully with mechanical circulatory support devices.


  • Open Access

    Progress with the HeartSaver ventricular assist device

    by Tofy Mussivand, Paul J Hendry, Roy G Masters, Mike King, Kevin S Holmes, Wilbert J Keon


  • Discussion

    by T Mussivand, P J Hendry, R G Masters, K S Holmes, W J Keon


  • Evolution of an Electrohydraulic Ventricular Assist Device Through In Vivo Testing

    by Paul J. Hendry, Roy G. Masters, Marilyn Keaney, Michael Bourke, Tofy Mussivand, Wilbert J. Keon, THE EVAD TEAM

    A totally implantable intrathoracic electrohydraulic ventricular assist device has been developed at the University of Ottawa Heart Institute. In vivo testing has been instrumental in its progressive development. A total of 15 experiments (4 acute, 11 performance) have been performed using male calves (62-117 kg). Data from the acute experiments, human fit trials, fluid dynamic studies, and hydraulic/energy efficiency analyses formed the basis for the development of a compact, single piece ventricular assist device called the Unified System in which the volume displacement chamber, motor, and blood chamber are housed within a compact 600 cc, 740 g unit. The performance experiments indicated that the unified system could support calves for periods up to 96 hr. The mean postoperative cardiac output was 7.1 +/- 0.7 L/ min (range = 4.9-11), mean blood pressure was 99.7 +/- 5.8 mmHg, and mean pulmonary artery pressure was 32.1 +/- 1.2 mmHg. The operative technique for intrathoracic implantation has been developed. The major problems encountered were of respiratory failure, improved by device repositioning in the calf; decreased blood inflow to the device that was improved by cannula redesign; circuit board fracture corrected by design modification; and a power supply problem that was limited to a single unit. The preliminary experiments have helped in the design modifications of the Unified System. The improved version of the system will undergo formal performance, reliability, and chronic in vivo testing before human implantation.


  • A Transcutaneous Energy and Information Transfer System for Implanted Medical Devices

    by Tofy Mussivand, Albert Hum, Marc Diguer, Kevin S. Holmes, Gino Vecchio, Roy G. Masters, Paul J. Hendry, Wilbert J. Keon

    During the last four decades there has been a rapid increase in the development and usage of medical devices. Currently, there are more than 500,000 devices on the market and 25,000 new devices enter the market each year. Many medical devices are now designed to be implantable (pacemakers, defibrillators, circulatory assist devices, artificial hearts, cochlear implants, neuromuscular stimulators, biosensors, etc.). Almost all of the active devices (those that perform work) and many of the passive devices (those that do not perform work) require a source of power. In addition, these devices need to be monitored and controlled, which can be accomplished by utilizing remote communication methods. A transcutaneous energy transfer system combined with a remote communications system has been developed and evaluated in vitro and in vivo (bovine, porcine, and human cadaver experiments). The energy transfer system can deliver up to 60 W with power transfer efficiencies between 60 and 83%. An automatically tuned, resonant frequency tracking method is used to obtain optimum power transfer over a range of operating conditions. The remote communications system can transfer digital data bidirectionally through intact skin at rates up to 9600 baud. The system transmits information by frequency modulating an 890 nm infrared carrier signal. The system has demonstrated satisfactory performance during multicenter evaluation with ventricular assist and total artificial heart devices. Design improvements have been identified, which will be implemented to produce an optimized system for energy transfer to and remote communications with various implantable medical devices.